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Cytomegalovirus (CMV) is one of the most important pathogens following solid-organ transplantation, and effective pre-
vention of CMV infection is a priority. The long-term control of CMV infection is dependent, in part, on the development
of CMV-specific T cells, and controversy exists regarding whether CMV prophylaxis may prevent this. Although preemptive
therapy is beneficial for the prevention of CMV disease, monitoring of viral levels in the blood does not always reflect what
is occurring in tissues. Persistent low-level CMV infection has been associated with indirect consequences, such as transplant-
associated vasculopathy, posttransplantation diabetes, an increased risk of opportunistic infection, and graft rejection. The
issues surrounding preventive strategies for CMV disease following solid-organ transplantation are reviewed. We argue that
prophylaxis is more effective than preemptive therapy; extending the duration of prophylaxis to the period of less intense
immunosuppression could protect patients from late-onset disease, as well as from the indirect effects of CMV infection.
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Despite significant improvements in di-
agnostic and therapeutic management, cy-
tomegalovirus (CMV) infection continues
to influence outcomes of both solid-organ
transplant (SOT) and hematopoietic stem
cell transplant (HSCT) recipients. CMV
has developed a number of strategies to
evade the host immune response and can
establish a life-long persistent and latent
infection in immunocompetent individ-
uals [1, 2]. However, in immunocompro-
mised hosts, as in HIV-infected individ-
uals and transplant recipients, CMV
reactivation can occur. In the absence of
any preventive therapy, 30%–75% of
transplant recipients develop CMV infec-
tion (table 1), and the reported incidence
of CMV disease is 8%–30% [3]. In ad-
dition to the direct consequences of CMV
infection [1], it is now accepted that CMV
infection is associated with a range of in-
direct effects [4–8], and recommendations
for updating the definitions of CMV in-
fection have been published [9].
Controversy exists concerning how best
to protect SOT recipients from the effects
of CMV infection. Ultimately, long-term
protection from CMV disease correlates
with the development of a CMV-specific
T cell immune response [10, 11], although
the CMV genome encodes a number of
gene products that can alter the host’s im-
munological functions [2]. The virus can
influence the production of various cy-
tokines and chemokines that can inhibit
natural killer and T cell responses, as well
as target humoral immune responses [12–
16]; in fact, it is these immunomodulatory
properties that may be responsible for the
indirect consequences of CMV infection
[17].
Late-onset CMV disease has emerged as
a significant complication for patients
(particularly if the donor is seropositive
[D+] and the recipient is seronegative
[R]) who receive 13 months of anti-
CMV prophylaxis, suggesting that anti-
CMV prophylaxis postpones the devel-
opment of CMV-specific immunity
following transplantation [18]. However,
interaction between CMV and the host
immune system is complex. Viral load in
the initial phase of active infection and
lower levels of persistent viral replication
correlate with CMV disease [19]. Thus, the
kinetics of viral replication may impact on
the ability of the host to mount a protec-
tive immune response, with the situation
further complicated in transplantation by
the use of immunosuppressive agents.
A main goal when selecting a preventive
strategy is to optimize long-term patient
outcomes. The 2 main strategies employed
by physicians are preemptive therapy or
prophylaxis therapy (table 1). The pre-
emptive approach has proven to be ben-
eficial in the prevention of CMV disease
and allograft rejection [20, 21]; however,
standard monitoring procedures do not
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Table 1. Definition of key terms.
Term Definition
CMV infection The presence of CMV in body fluid or a tissue specimen as determined by DNA techniques, culture, or antigen
tests
CMV disease CMV infection manifesting with signs and symptoms of fever, malaise, leukopenia (CMV syndrome), and/or
documented CMV invasive disease into organs (tissue invasive disease)
Late-onset disease CMV disease occurring after the cessation of antiviral prophylaxis
Preemptive therapy Regular monitoring of patients to identify CMV viremia and instigation of therapeutic intervention only
when the virus is detected
Prophylaxis therapy The administration of antiviral therapy for a predefined time (usually 3 months) to all patients at risk for CMV
infection
NOTE. CMV, cytomegalovirus.
Figure 1. Percentage of lung transplant recipients who were free from cytomegalovirus (CMV)
infection and disease following prolonged prophylaxis with valganciclovir for !100 days ( ),np 18
100–179 days ( ), 180 days ( ), 270 days ( ), and 365 days ( ).np 11 np 21 np 20 np 20 P ! .02
for 180, 270, or 365 days versus !100 or 100–179 days. P value was not significant for 180 days
versus 270 days versus 365 days. Reproduced with permission from Zamora et al. [34].
detect local CMV reactivation, risking the
development of organ-specific disease if
viral load supersedes disease thresholds
prior to detection of virus in the blood
[21–23]. The development of a CMV-spe-
cific immune response is paramount for
lifelong protection against CMV infection
and disease. Preemptive therapy may allow
the development of effective CMV-specific
immunity in the early posttransplantation
period, thereby reducing the risk of late-
onset CMV disease; however, this ap-
proach does not offer full protection
against all of the indirect effects of CMV
infection [20]. It is important to note that
persistent low-level viremia can indirectly
impact upon long-term transplantation
outcomes, such as the development of
transplantation-associated cardiovasculo-
pathy [24], opportunistic infection, or
posttransplantation diabetes mellitus [6],
and thereby decrease overall patient and/
or graft survival.
This review will argue that extending
the duration of prophylaxis to a period of
less intense immunosuppression—yet to
be defined—should enable the develop-
ment of CMV-specific immune responses
and, thus, protect against late-onset dis-
ease while preventing the indirect effects
of CMV infection.
EFFECTIVE PREVENTION
OF CMV INFECTION:
CONSIDERATIONS
FOR LATE-ONSET DISEASE
Several antiviral agents are available for the
prevention and treatment of CMV infec-
tion, of which intravenous ganciclovir and
the oral prodrug of ganciclovir, valganci-
clovir, are most commonly prescribed. Al-
though both prophylaxis and preemptive
strategies are currently employed, the ma-
jority of clinical evidence derives from
studies involving prophylaxis, because the
number of reported preemptive trials are
relatively few [25, 26]. These clinical stud-
ies have consistently demonstrated that
CMV prophylaxis is beneficial in reducing
the risk of CMV disease [27–29] and the
indirect sequelae associated with CMV in-
fection [20, 21, 25, 27]. Nevertheless, pro-
phylaxis has also been associated with the
development of late-onset CMV disease,
the severity of which (at least in renal
transplantation) is usually mild.
The PV16000 trial, which assessed the
comparative efficacy of 100 days of pro-
phylaxis with valganciclovir versus oral
ganciclovir in D+/R patients, reported
an incidence of CMV disease at 12 months
after transplantation of 17.2% and 18.4%
for valganciclovir and oral ganciclovir, re-
spectively. The vast majority of patients
who developed CMV disease did so after
the discontinuation of prophylaxis (i.e.,
they experienced late-onset disease) [28],
as has been reported by other investigators
[30, 31]. Such studies have led to sugges-
tions that the benefits of prophylaxis are
confined to the early posttransplantation
period [32].
Evidence suggesting that extending the
period of antiviral prophylaxis will avoid
the problem of late-onset disease is now
accumulating. A recent study compared
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Figure 2. Enumeration of cytomegalovirus (CMV)–specific CD4+ and CD8+ T cells in primary CMV infection. Graphs show the frequencies of CMV-
specific CD4+ T cells as determined by intracellular staining for CD69 and IFN-g following stimulation (empty circles), CMV-specific CD8+ T cells as
determined by tetramer binding (solid circles), and the first specific antibody appearance (dotted vertical line) in relation to CMV load (triangles) in 1
asymptomatic representative patient (A) and 1 symptomatic patient (B). Solid vertical line denotes start of ganciclovir therapy. In this study of donor-
seropositive, recipient-seronegative renal transplant recipients, CMV-specific effector memory CD4+ T cell responses (in peripheral blood) appeared
prior to CMV-specific antibodies and CD8+ T cell responses, with all responses directed to the clearance of virus. In symptomatic patients, CMV-
specific effector memory CD4+ T cell responses were delayed relative to CMV-specific CD8+ T cell and antibody responses and only appeared after
the initiation of antiviral therapy. In this study, these CMV-specific CD4+ T cell responses appeared to determine adequate viral clearance. Reproduced
with permission from Gamadia et al. [47].
the incidence of CMV disease among
high-risk D+/R kidney transplant recip-
ients receiving a 24-week course of oral
ganciclovir prophylaxis with the incidence
among those receiving a 12-week course.
The proportion of patients who experi-
enced symptomatic CMV infection by the
end of the first year after transplantation
was considerably lower among those re-
ceiving the 24-week course of prophylaxis
than among those receiving the 12-week
course (7% vs. 31%; ). Further-Pp .001
more, 24 weeks of ganciclovir prophylaxis
appeared to be safe and effective [33].
Lung transplant recipients are at high-
risk for CMV disease. Zamora et al. [34]
investigated the length of prophylaxis re-
quired to significantly reduce the inci-
dence of CMV infection and disease. Free-
dom from CMV infection was determined
180 days after cessation of valganciclovir
and was significantly greater ( )P ! .02
among patients receiving prophylaxis for
180, 270, or 365 days (90%, 95%, and 90%
of patients, respectively) than it was
among patients receiving prophylaxis for
100–179 days or !100 days (64% and
59%, respectively) (figure 1) [34]. This
study demonstrates that the benefits of ex-
tended prophylaxis persist beyond the pe-
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Figure 3. Five-year follow-up data for patients with persistent cytomegalovirus (CMV) infection
of the graft, showing graft survival uncensored for death (A; ) and death-censored graftPp .020
survival (B; ) in patients with persistent CMV infection, compared with patients withPp .041
nonpersistent or no CMV infection in the graft. Reproduced with permission from Helantera et
al. [67].
riod of administration. A concern with the
strategy of extended prophylaxis is that
this approach may only postpone the on-
set of CMV disease. However, Zamora et
al. [34] have demonstrated that, by in-
creasing the duration of prophylaxis to at
least 180 days, 90% of at-risk lung trans-
plant recipients remained disease-free
throughout the first year after trans-
plantation.
A randomized, double-blind, placebo-
controlled multicenter trial—the Im-
proved Protection Against Cytomegalo-
virus in Transplant (IMPACT) study—has
recently been initiated. This study will de-
termine the comparative efficacy of 100
days versus 200 days of valganciclovir pro-
phylaxis when given for the prevention of
CMV disease in high-risk (i.e., D+/R)
kidney allograft recipients. The primary
end point of the study will be the pro-
portion of patients who develop CMV dis-
ease within the first 12 months after trans-
plantation. The IMPACT study will also
assess allograft rejection, opportunistic in-
fection, patient and/or graft survival, and
the occurrence of posttransplantation di-
abetes mellitus.
The concern regarding the possible de-
velopment of antiviral resistance is a le-
gitimate one. Risk factors for the emer-
gence of ganciclovir-resistant CMV
include treatment of D+/R patients,
prolonged use of oral ganciclovir, and the
use of more-potent immunosuppressive
therapy [35–37]. However, ganciclovir re-
sistance has also been observed in patients
receiving preemptive therapy [36]. More-
over, ganciclovir-resistant CMV strains
were not associated with the 3-month
course of valganciclovir prophylaxis ad-
ministered to SOT recipients in the
PV16000 study [38–40]. The IMPACT
study will also provide appropriate
answers.
When making the decision to extend
the duration of CMV prophylaxis, the
question of cost must be considered. Re-
cent studies assessing the costs of a pre-
emptive strategy relative to a standard pro-
phylaxis course have either shown the
overall costs to be similar [41] or shown
prophylaxis to be the more cost-effective
approach (in renal transplantation) [42].
Although extending the duration of ther-
apy will increase the total drug-associated
costs, this additional cost should be offset
by a reduction in the costs associated with
the management and treatment of late-
onset CMV disease and in those associated
with the indirect consequences of CMV
infection.
CMV-SPECIFIC IMMUNITY:
THE IMPACT OF ANTIVIRAL
THERAPY
Preventive strategies have undoubtedly
improved the prognosis for transplant re-
cipients who are at risk of developing
CMV disease. However, the emergence of
late-onset disease emphasizes that the es-
tablishment of an effective cellular CMV-
specific immune response remains essen-
tial for the long-term control of viral
replication [10, 43, 44]. Both CD4+ and
CD8+ CMV-specific T cells are important
for controlling CMV infection (figure 2)
[45–47], but CD8+ T cells must be effec-
tively primed upon their first encounter
with CMV to prevent a defective response
upon a second encounter [45, 46, 48, 49].
The importance of CMV-specific im-
munity in organ transplantation is high-
lighted by the correlation between patient
exposure to CMV before transplantation
and the development of CMV disease. D+/
R transplant recipients are immunolog-
ically naive with respect to CMV and are
at the greatest risk of developing CMV
disease after transplantation. On the other
hand, prior exposure to CMV (i.e., being
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Table 2. Meta-analysis of relative risk (RR) for all-cause mortality, allograft rejection,
cytomegalovirus (CMV) organ disease, CMV infection, and opportunistic infections for
universal prophylaxis, compared with preemptive therapy clinical trials.
Variable, study
RR (95% CI)
With prophylaxis P
With preemptive
therapy P
All-cause mortality
[19] 0.62 (0.40–0.96) .032 0.94 (0.32–2.76) .90
[22] 0.63 (0.43–0.92) .02 …
Allograft rejection [19] 0.74 (0.59–0.94) .012 0.47 (0.24–0.91) .026
CMV organ disease
[19] 0.20 (0.13–0.31) .001 0.28 (0.11–0.69) .003
[22] 0.42 (0.34–0.52) .0001 …
CMV infection [22] 0.61 (0.48–0.77) Not applicable
Opportunistic infections
Bacterial and fungal [19] 0.49 (0.36–0.67) No effect
Bacterial [22] 0.65 (0.44–0.96) …
Fungal [22] 0.58 (0.19–1.73) …
Non-CMV viral [19] 0.16 (0.12–0.23) Not evaluated
Protozoa [22] 0.31 (0.01–0.99) …
an R+ patient) is associated with the gen-
eration of CMV-specific immune memory
[46]; thus, these patients are generally bet-
ter able to control viral replication than
are their D+/R counterparts. This is re-
flected by the classification of R+ patients
as being at only “moderate risk” of de-
veloping CMV disease. However, R+ pa-
tients who receive enhanced immuno-
suppressive therapy, such as polyclonal
antilymphocyte antibodies or anti-CD3
monoclonal antibodies, are considered to
be at higher risk for CMV disease, because
they are less able to mount an effective
immune response; therefore, it is recom-
mended that these patients routinely re-
ceive CMV prophylaxis [3, 50, 51].
Proponents of the preemptive approach
to CMV prevention have argued that, be-
cause viral antigens and, therefore, low-
level viral replication are required to prime
the host immune system, prophylactic
strategies may prevent efficient priming of
the CMV-specific immune response by
completely suppressing viral replication,
particularly in D+/R– transplant recipients
[18, 52, 53].
Studies, primarily involving HSCT re-
cipients, show that ganciclovir can impair
the reconstitution of CMV-specific T cell
responses by either preventing in vivo
priming or by directly inhibiting T cell
proliferation [44, 53]. However, Hakki et
al. [54] analyzed factors affecting the re-
covery of CMV-specific CD4+ and CD8+
T cell immunity 3 months after trans-
plantation in a cohort of 201 HSCT re-
cipients. In their univariate and multivar-
iate analyses, they found that high-dose
steroids and CD4+ T cell count !100
109 cells/L were significantly associated
with impaired functional CD4+ T cell re-
covery and that high-dose steroids, bone
marrow as stem cell source, and CD8+ T
cell count ! cells/L were signifi-950 10
cant predictors of impaired CD8+ T cell
function. Notably, this study showed that
there was no difference in immune recon-
stitution between patients who received
ganciclovir prophylaxis and those who re-
ceived preemptive therapy, although pa-
tients receiving ganciclovir who had
subclinical CMV reactivation had a sig-
nificantly improved recovery of T cell
function [54].
The immune response to viral infec-
tions in HSCT recipients is extremely
complex, with potential contributions
from both the donor and recipient im-
mune systems. In D+/R SOT recipients,
immunity to CMV will require efficient
priming of naive T cells; however, HSCT
recipients (other than D/R recipients)
cannot be described as immunologically
naive with respect to CMV. In addition,
immune recovery following HSCT will be
influenced by a number of other factors,
including the source of the stem cells, the
degree of MHC mismatching, and the type
of immunosuppressive or conditioning
regimen, which may vary considerably
from those used in treating SOT recipients
[54–56]. It may not, therefore, be appro-
priate to extrapolate findings obtained in
the context of HSCT to SOT.
A subanalysis of D+/R SOT recipients
who were enrolled in the PV16000 clinical
trial sought to identify risk factors for late-
onset disease and found that IgG sero-
conversion occurred in 26.9% of D+/R
SOT recipients by the end of the 100-day
prophylactic period and in 63.4% and
75.3% of patients by 6 and 12 months
after transplantation, respectively [57]. Al-
though seroconversion by the end of pro-
phylaxis was not predictive of subsequent
disease, IgG serostatus became predictive
by 6 months and 12 months after trans-
plantation [57]. Importantly, seroconver-
sion occurred while patients were receiv-
ing valaciclovir or ganciclovir,
demonstrating that prophylaxis permits
the development of CMV-specific hu-
moral immunity. Furthermore, of the
26.9% of patients who experienced sero-
conversion during prophylaxis, only 1%
experienced CMV disease during this pe-
riod [57]. Consistent with these findings,
a case study of a kidney and pancreas
transplant recipient at high risk for CMV
reported the development of anti-CMV
IgG and an expansion of activated CMV-
specific CD8+ T cells during primary
CMV infection in the patient despite gan-
ciclovir prophylaxis [58].
Studies involving SOT recipients, there-
fore, suggest that the CMV-specific im-
mune response is not suppressed by an-
tiviral prophylaxis, although a full
understanding of the impact of antiviral
agents on the development of CMV-spe-
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cific immunity requires further investi-
gation. A significant advantage of pro-
phylaxis is the reduction in the incidence
of primary infection during the prophy-
lactic period. In the absence of prophy-
laxis, most episodes of CMV DNAemia
occur within 100 days after transplanta-
tion [41], suggesting that development of
the CMV-specific immune response will
occur within this time frame. Extending
the duration of prophylaxis until the time
of less intense immunosuppression will in-
crease the probability that primary infec-
tion will occur at a time when the patient
is able to mount a more effective CMV-
specific response. This should enable a
more sustained control of viral replication,
thereby inhibiting the development of
CMV disease and/or recurrent episodes of
CMV infection.
PROGRESSION TO CMV
DISEASE: THE IMPACT OF
VIRAL KINETICS
CMV-specific T cells have been shown to
mediate protection from CMV disease by
effectively limiting the systemic viral load
[43]. The relationship between the quan-
tity of CMV detected in blood and the
development of symptomatic CMV dis-
ease was first reported in 1975 [59]. Since
this time, a number of investigators have
confirmed viral load to be a significant risk
factor for the development of CMV dis-
ease [60–62] and a useful prognostic in-
dicator for recipients of SOT [19, 63]. It
has been suggested that the high viral load
observed in lung transplant recipients,
compared with the recipients of other
transplants, might explain the classifica-
tion of lung transplant recipients as being
at high risk for developing CMV disease
[23, 50].
With the advent of highly sensitive
quantitative methods, a more complex
picture of the relationship between viral
turnover and CMV disease has emerged.
The degree of viral replication is strongly
associated with progression to CMV dis-
ease in liver transplant recipients [64]. Pre-
emptive ganciclovir therapy was associated
with the persistence of low-level viral rep-
lication in 21% of liver transplant patients,
33% of whom went on to develop CMV
disease [64]. Consistent with this, analysis
of viral load kinetics in SOT recipients
with CMV disease showed that a delay or
failure in clearance of the virus were im-
portant predictors of disease relapse [65].
Recently, a statistical model incorporating
viral load data from 142 liver transplant
recipients suggested that peaks in viral
load contributed less to disease progres-
sion than did phases of low viral load with
equal amounts of viral turnover. Of in-
terest, the model accurately predicted the
time to onset of CMV disease [66]. These
studies suggest that a low level of viral
replication—as occurs with preemptive
therapy—is not protective against pro-
gression to CMV disease but may actually
predispose to CMV disease and/or recur-
rent CMV infection.
INDIRECT SEQUELAE OF CMV
INFECTION
Recent evidence has led to expansion of
the definitions needed for the manage-
ment of CMV infection and disease in
SOT recipients [9]. In addition to causing
end-organ disease, CMV infection has
been associated with considerable allograft
pathology (figure 3) [67], including ath-
erosclerosis, bronchiolitis obliterans, van-
ishing bile duct syndrome, vascular dis-
ease, and both acute and chronic graft
rejection [5, 8, 17, 67–69]. Animal models
have provided important insights into the
mechanisms responsible for the deleteri-
ous effects of CMV on graft function. For
example, prolonged increased expression
of intercellular adhesion molecule type 1
and vascular cell adhesion molecule type
1 was observed in rat kidney allograft re-
cipients infected with CMV, with concom-
itant increased infiltration of inflamma-
tory cells expressing their ligands, and was
associated with accelerated chronic allo-
graft nephropathy [70]. An experimental
model of liver allograft rejection showed
prolonged upregulation of adhesion mol-
ecules that mediate lymphocyte adhesion
in inflammatory sites, and this was asso-
ciated with concomitant CMV infection
[71].
Clinical studies also demonstrated that
antiviral prophylaxis is beneficial in pro-
tecting against the indirect effects of CMV
infection. A retrospective analysis of
CMV-seropositive heart transplant recip-
ients [72] observed a lower incidence of
transplant-associated coronary artery dis-
ease in patients receiving ganciclovir pro-
phylaxis than in patients receiving placebo
(38% vs. 55%) [72]. Furthermore, a lack
of ganciclovir prophylaxis was associated
with a significantly increased relative risk
for transplant-associated coronary artery
disease (relative risk, 2.7 vs. 2.9; )P ! .01
[72]. Importantly, a recent study has
shown that suppression of subclinical
CMV replication during antiviral prophy-
laxis resulted in a reduced relative risk for
acute rejection and a slower progression
of cardiac allograft vasculopathy [73]. Val-
ganciclovir prophylaxis has also been
shown to lower the incidence of various
herpesvirus infections, such as infections
due to human herpesvirus 6, human her-
pesvirus 8, Epstein-Barr virus, and vari-
cella zoster virus, in SOT recipients [74],
and studies have demonstrated that im-
proved patient and graft survival and a
decreased risk of biopsy-proven rejection,
as well as a decrease in the incidence of
opportunistic infections, are associated
with prophylaxis [20, 75–77]. Recent
meta-analysis and systematic reviews of
CMV prophylaxis and preemptive therapy
have shown that both of these approaches
were effective at reducing CMV-associated
end-organ disease and allograft rejection,
but only CMV prophylaxis was effective
in reducing CMV disease, CMV-related
mortality, all-cause mortality, and disease
caused by opportunistic infections (table
2) [20, 21, 25].
CONCLUSIONS
CMV infection continues to present a sig-
nificant challenge to transplant clinicians
involved in the care of transplant recipi-
ents. Successful long-term prevention of
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CMV disease requires the generation of a
CMV-specific T cell response. How this
might be better achieved is much debated,
because it is extremely difficult to dissect
the relative contributions of the various
factors impacting on the development of
CMV-specific immunity.
Both prophylaxis and preemptive strat-
egies have been shown to be effective for
disease prevention. Data associating CMV
with indirect sequelae and their significant
consequences on long-term graft and pa-
tient outcomes are accumulating, and the
number of studies demonstrating the ben-
efit of CMV prophylaxis in reducing these
sequelae is increasing. Systematic reviews
and meta-analyses show that prophylaxis
is better for protecting against the indirect
effects of CMV infection and, thus, may
become the preferred preventive strategy.
Future studies will indicate whether ex-
tending the duration of prophylaxis be-
yond the period of intense immunosup-
pression (e.g., up to 6 months) can not
only lower the incidence of CMV disease
but also have a beneficial effect on graft
function and overall outcomes.
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